R1 RCM (NASDAQ:RCM) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of R1 RCM (NASDAQ:RCM) from a hold rating to a sell rating in a research report report published on Saturday morning, BidAskClub reports.

Several other equities research analysts have also recently commented on the company. Zacks Investment Research cut R1 RCM from a hold rating to a sell rating in a research note on Thursday, May 7th. Royal Bank of Canada assumed coverage on R1 RCM in a research note on Monday, April 20th. They issued an outperform rating and a $12.00 target price on the stock. SVB Leerink assumed coverage on R1 RCM in a research note on Monday, April 13th. They issued a market perform rating and a $10.00 target price on the stock. Finally, ValuEngine upgraded R1 RCM from a hold rating to a buy rating in a research note on Tuesday, March 17th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $13.43.

R1 RCM stock opened at $10.85 on Friday. The firm has a market capitalization of $1.24 billion, a P/E ratio of -542.23, a PEG ratio of 12.03 and a beta of 0.52. R1 RCM has a 1 year low of $7.12 and a 1 year high of $13.99. The business has a 50-day moving average of $10.85 and a 200-day moving average of $11.31. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 14.63.

R1 RCM (NASDAQ:RCM) last posted its earnings results on Tuesday, May 5th. The healthcare provider reported $0.05 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.03). R1 RCM had a return on equity of 174.42% and a net margin of 2.44%. The company had revenue of $320.50 million for the quarter, compared to analyst estimates of $318.76 million. During the same quarter in the previous year, the firm posted ($0.04) earnings per share. R1 RCM’s quarterly revenue was up 16.1% compared to the same quarter last year. Research analysts anticipate that R1 RCM will post 0.08 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in RCM. Amalgamated Bank increased its holdings in shares of R1 RCM by 7.2% during the 4th quarter. Amalgamated Bank now owns 19,520 shares of the healthcare provider’s stock worth $253,000 after acquiring an additional 1,319 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of R1 RCM by 0.9% during the 1st quarter. Rhumbline Advisers now owns 141,622 shares of the healthcare provider’s stock worth $1,287,000 after acquiring an additional 1,323 shares during the last quarter. Americana Partners LLC acquired a new position in shares of R1 RCM during the 4th quarter worth approximately $25,000. Principal Financial Group Inc. increased its holdings in shares of R1 RCM by 6.3% during the 1st quarter. Principal Financial Group Inc. now owns 36,024 shares of the healthcare provider’s stock worth $327,000 after acquiring an additional 2,146 shares during the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of R1 RCM by 19.0% during the 4th quarter. ProShare Advisors LLC now owns 14,072 shares of the healthcare provider’s stock worth $183,000 after acquiring an additional 2,248 shares during the last quarter. Institutional investors own 74.28% of the company’s stock.

R1 RCM Company Profile

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.

Featured Story: What does a bar chart display?

Analyst Recommendations for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.